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CASE PRESENTATION
A 48-year-old African woman presented at the
Sheffield Kidney Institute complaining of lethargy as
well as nausea and vomiting. She had always lived in
a sub-Saharan African country devastated over the last
quarter-century by war and internal conflict. Over the last
3 years, her health had been deteriorating, with progres-
sive swelling of her legs. She had had nocturia for the last
5 to 6 years. She also mentioned that her two pregnan-
cies had been complicated by severe hypertension and
edema and were therefore terminated early. She was not
followed up subsequently, and she returned to her village,
which has only one general medical practitioner and a
witch doctor. She also gave a family history of chronic
kidney disease (CKD); her older brother died from end-
stage renal disease (ESRD) a few years ago.
When she sought a medical opinion in the capital city
of her country one year prior to her arrival in Sheffield,
she was told that she had severe hypertension, heavy pro-
teinuria, and progressive renal insufficiency. Some medi-
cation was dispensed to her, but she failed to renew her
prescription because of its prohibitive cost. When her
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condition deteriorated, she returned to the capital city’s
main hospital, where ESRD was diagnosed. She was told
that little could be offered to her in view of the lack of
dialysis facilities. She was advised to go back to her vil-
lage to die. This she would not accept and decided to visit
her daughter, who had sought asylum in the UK a few
months prior to her own arrival.
When the patient presented to the Sheffield Kidney
Institute, she was severely anemic; her hemoglobin was
6.7 g/dL with significant microcytosis (MCV, 72 fl) and
hypochromia (MCHC, 28 g/dL). The serum urea was
67 mmol/L and serum creatinine level was 1299 lmol/L
(14.8 mg/dL). She was hyperkalemic (K, 6.8 mmol/L)
and severely acidotic (serum bicarbonate, 12 mmol/L).
Her serum protein and albumin were low at 46 g/L and
18 g/L, respectively. Serum calcium was low, 2.1 mmol/L,
and phosphorus raised, 2.2 mmol/L, with a high intact
PTH level of 576 pg/mL. Clinically, the patient was fluid
overloaded with marked peripheral edema, raised jugular
venous pressure, and bilateral basal lung crepitations. Her
blood pressure was high, 187/94 mm Hg, and cardiac aus-
cultation revealed a gallop rhythm. Urinalysis showed:
+1 protein and 1+ blood. The 24-hour urinary protein
excretion was 0.9 g. A chest radiograph revealed marked
cardiomegaly and congested lung fields. Ultrasound scan
of her kidneys showed them to be small, approximately
6 to 7 cm.
It was apparent that the patient was in end-stage
renal failure and required the immediate initiation of
hemodialysis, which was instituted through a tunneled
jugular venous catheter. Over the subsequent 4 weeks,
her condition started to improve, her blood pressure was
normalized through fluid removal, her anemia improved
with intravenous iron supplementation and the institu-
tion of erythropoietin treatment, and attention started to
be paid to her severe malnutrition.
DISCUSSION
PROF. MEGUID EL NAHAS (Professor of Nephrol-
ogy, Sheffield Kidney Institute, Sheffield Teaching Hos-
pitals NHS Trust, Sheffield, UK): This unfortunate lady
is a sad example of an all-too-common problem we en-
counter in the UK and other Western countries, namely,
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Fig. 1. Purchasing power parity (PPP) and
prevalence of ESRD in selected developing
countries (modified from [4]).
asylum-seekers and immigrants who come to the West
not as much for political or economic motives but for
medical treatment. Her case highlights the plight of mil-
lions of patients worldwide in developing countries who
are denied access to renal replacement therapy (RRT)
because of a lack of facilities and resources.
Globally, the number of patients with end-stage renal
disease (ESRD) is increasing steadily. Currently, more
than 1.6 million individuals worldwide undergo RRT,
mostly hemodialysis. Most of these patients (90%) live in
the developed world, which accounts for only 20% of the
world population [1–3]. In fact, 56% of all patients receiv-
ing RRT live in only 5 countries, the United States (US),
Japan, Brazil, Italy, and Germany, which represent only
12% of the global population [1]. The stark and alarming
reality is that 112 countries representing a population of
600 million remain without RRT [1]. It is therefore not
surprising that 1 million patients die every year world-
wide from ESRD. Most countries in sub-Saharan Africa,
where our patient comes from, have few or no RRT facili-
ties [4]. In Asia, the Indian sub-continent has very limited
facilities for a growing population (exceeding 1 billion).
In fact, India has a prevalence of patients on RRT of less
than 15/million of population (pmp) when at least 200 to
300 pmp is expected [1, 5]. In China, the prevalence varies
from around 100 pmp in major urban centers to as little
as 3 to 5 pmp in huge and overpopulated rural areas [1,
6]. Similar discrepancies have been described in Russia,
where the annual incidence of ESRD is as low as 15 pmp
[1, 7]. Comparing this to the annual incidence in the US
of over 360 pmp (prevalence: ∼1400 pmp) and Europe
of around 150 pmp (prevalence: ∼700 pmp), it becomes
apparent that a huge gap in resources prevents the devel-
oping, low-income countries from providing treatment to
an ever-increasing number of patients with ESRD [1–3].
In fact, in the developing world, the prevalence of ESRD
is proportionate to national income and economy (Fig. 1).
As there are no major differences in incidence of ESRD
among developing countries, it is most likely that the ma-
jor, if not sole, determinant of prevalence is the capacity
and sustainability of RRT programs; these are all finan-
cially determined.
This gloomy situation is likely to worsen over the next
decade, as the number of patients with ESRD appears to
be rising annually by 5% to 8%, with an expected 2 million
patients undergoing RRT by 2010 [2, 8]. Undoubtedly,
few of these will be in the developing world, where the
cost of such treatment is prohibitive; the expected cost in
the US by 2010 to treat more than 600,000 patients will
reach around $29 billion [1–3].
The global challenge in nephrology over the next
decade is not to provide RRT to the millions who cannot
afford it; nor is it to encourage these patients to seek treat-
ment in the West, where resources are already at break-
ing point. Instead, the nephrology community should try
to shift the emphasis away from treatment of ESRD to
the early detection and prevention of progressive chronic
kidney disease (CKD). Early detection and prevention of
CKD should in principle reduce the global burden of this
chronic non-communicable disease through management
of risk factors and interventions aimed at slowing the de-
velopment and/or the progression of CKD. To achieve
such a goal, it is imperative that we embark on global
screening programs for CKD.
In this Forum, I will review the rationale for such pro-
grams and the requirements for their implementation.
For a screening program to be successful, certain crite-
ria have to be met: The disease screened must be com-
mon. Its natural history and stages should be well defined.
Screening tests should be reliable and affordable. The
prognostic significance of detected abnormalities must be
established. Interventions must exist that can successfully
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treat those with the disease. Finally, the entire process of
screening and treatment must be cost-effective. I will ad-
dress these issues in relation to CKD, and will examine
staffing and financial issues pertinent to the implementa-
tion of detection and prevention programs.
Is screening warranted?
In whole population terms, the number of ESRD pa-
tients worldwide represents a small percentage (0.1%).
Therefore, patients with CKD have long been under-
served by many health authorities and governments. In
developing countries, this has been compounded by other
conflicting health priorities, including those of communi-
cable diseases, especially AIDS. However, emphasis is
slowly shifting both in the West and in the developing
world as the realization of the scale of non-communicable
diseases, including CKD, and their impact on health care
is growing.
In the US, data derived from the third National Health
and Nutrition Examination Survey (NHANES III) sug-
gest that as many as 11% of the entire adult US popula-
tion is affected by some degree of CKD [9]. In fact, they
estimated that 5.9 million have stage 1 CKD with normal
renal function and GFR >90 mL/min, whereas another
5.3 million have stage 2 (GFR 89–60 mL/min) [9]. Studies
in other Western countries show that around 6% to 7%
of the population has albuminuria, with around 0.6% to
0.7% overt proteinuria [10]. In Australia, the AusDiab
study showed that 10% of those screened had impaired
renal function; 16% of those had some degree of kidney
involvement, impaired renal function, hematuria, and/or
proteinuria [11]. Studies in developing countries such as
Singapore showed a similar prevalence of CKD [12].
Before we become alarmed by these findings and as-
sume that millions of individuals worldwide are head-
ing toward RRT, we need to be somewhat critical of
these analyses and raise some issues. The NHANES
III data were cross-sectional in nature, with individu-
als tested once. The variability of measurements of al-
buminuria/proteinuria, as well as those based on serum
creatinine estimation, is quite high, and rendering defini-
tive conclusions based on such cross-sectional analysis
somewhat doubtful. Albuminuria/proteinuria, as we all
know, can be affected by a range of factors, including
posture, timing of the sample, exercise, infection, and
pyrexia. Also, studies have shown that with repeat testing
of a random population, only 60% remain positive [9, 13,
14]. Similarly, measurements of serum creatinine require
standardized calibration across laboratories, as variation
in a given sample estimate can reach 25% [14]. The cal-
culation of glomerular filtration rate (GFR) based on the
MDRD formula can add additional bias to the estima-
tion of the number of patients with different stages of
CKD, as its accuracy in the estimation of GFR has not
been validated for general screening, for testing individ-
uals with normal renal function, or in ethnic minorities
[15]. In fact, recent data suggest that Hispanic Ameri-
cans, particularly those of Cuban descent, have higher
serum creatinine levels when compared to whites [16].
Whether this discrepancy reflects a higher prevalence of
CKD in this ethnic minority or merely differences in body
mass and creatinine handling is unknown, but the find-
ing highlights difficulties with estimation of renal func-
tion based on serum creatinine levels. Also, analysis of
individuals with reduced GFR does not always take into
account age-related changes; it is unlikely that elderly
individuals with a mildly reduced GFR would have the
same prognosis as patients with chronic glomerulonephri-
tis with hypertension, proteinuria, and declining renal
function. A cross-sectional estimation of renal function
does not provide insights into the progressive nature of
CKD. Debates should be informed by more research and
epidemiologic data, including longitudinal studies. This is
particularly relevant to developing countries, where re-
sources are scarce and priorities in health care must be
carefully justified.
Care for patients reaching ESRD and requiring RRT
is costly. In the US, the current annual cost of $17 billion
is expected to climb to $29 billion by 2010 [2, 17]. In
Europe, dialysis alone consumes about 2% of the health
care budget, with only a small fraction (<0.1%) of the
population requiring treatment [3]. The global cost of
ESRD treatment has been estimated at $1 trillion. Only
high-income economies can afford such high health care
costs [1, 2]; developing countries have other health care
priorities, including combating communicable diseases
such as AIDS, tuberculosis, and malaria.
The cost of CKD is compounded by the high morbid-
ity (hospitalization cost) and mortality (loss of income-
generating power) attributable directly to the disease
and indirectly to the associated cardiovascular disease
(CVD). In fact, albuminuria, proteinuria, and renal in-
sufficiency are important risk markers for the increased
morbidity and mortality due to CVD [10, 18–21], espe-
cially in patients with diabetes mellitus, hypertension, is-
chemic heart disease, and congestive heart failure [18]. In
addition, the presence of CKD is associated in the general
population with an increase in all-cause death as well as
cardiovascular mortality [20, 21]. In the developing world,
non-communicable diseases including CVD are increas-
ing at an alarming rate because of the urbanization and
westernization of lifestyle. Little doubt exists that CKD
is a costly disease in financial as well as human terms, and
that it warrants screening and prevention.
Natural history and stages of CKD
The risk markers and factors implicated in the de-
velopment of CKD include non-modifiable as well as
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modifiable factors. The former include old age, male gen-
der, race (African and Asian) as well as some genetic
variations (polymorphisms) affecting putative genes
(reviewed in [22]). Modifiable factors include hyper-
tension, proteinuria, dyslipidemia, obesity, and smoking
(reviewed in [22]). Excessive alcohol consumption
(>2 units/day) has been linked in one survey to the
development of CKD. The role of factors such as
chronic consumption of analgesics and nonsteroidal anti-
inflammatory drugs remains debatable. Also, herbal
remedies have been implicated in the development of
chronic interstitial renal disease. Environmental pollu-
tion and exposure to heavy metals, including lead, have
been associated with a higher prevalence of CKD [7].
Finally, there is little doubt that many of the communi-
cable, infectious diseases affecting the developing world
such as malaria, schistosomiasis, hepatitis C, and HIV in-
crease the risk of developing CKD. In established CKD,
a faster rate of progression has been associated with sys-
temic hypertension, proteinuria, hyperlipidemia, smok-
ing, and obesity (reviewed in [22]).
Recently, K/DOQI put forward a new classification of
CKD, with 5 stages based on the level of renal functional
impairment [23]. This classification has been enthusias-
tically adopted by most. While useful in simplifying the
categorization of CKD, this classification has its limita-
tions. Stage 1 CKD, for instance, allows for the inclusion
of individuals with minimal renal functional and/or radi-
ologic abnormalities that might prove of little long-term
clinical relevance. To categorize those individuals as suf-
fering from CKD might be misguided in more than one
respect, not the least psychologically [24]. It would be
more appropriate to divide patients into those with some
defined abnormalities, such as isolated hematuria or mi-
croalbuminuria, and those with impaired renal function.
The latter might warrant sub-classifications based on the
presence or absence of progression and the associated
risk factors such as hypertension and proteinuria [24].
The K/DOQI classification has been of good administra-
tive and educational value in simplifying CKD and gener-
ating a standardized global definition. It will undoubtedly
undergo revisions with time that will render it more and
more accurate and clinically relevant. In fact, it already
has been the subject of a recent position statement from
Kidney Disease: Improving Global Outcomes (KDIGO)
[25].
Having defined the stages of CKD, it is imperative that
we appreciate that they are not necessarily biologically
linked. A patient in stage 1 is not bound to flow through
2, 3, and 4 and thus end up in stage 5. In fact, little is known
about the natural history of stages 1 and 2 CKD. We all
are familiar with the assumption that most patients with
advanced renal insufficiency (stages 3–5) will eventually
require RRT. While this might be true for most, it is not
invariable; numerous analyses have shown that a sizable
percentage of patients in stages 3 and 4 have stable re-
nal function. In an analysis of the percentage of patients
in different stages of CKD followed up at the Sheffield
Kidney Institute, we found that as many as 27%, 34%, and
38% of patients in stages 3, 4, and 5, respectively, were
non-progressors, based on an estimated GFR calculated
from the MDRD 4 variables formula, over a retrospective
observation period of approximately 5 years (Al Tahir G,
Abdul Wahab H, MMed Sci Dissertations, University of
Sheffield 2004, unpublished observations). It is unknown
what proportion of patients classified as having stage 1
and 2 or even 3 will progress to ESRD (stage 5). More
research is needed to validate modeled projections of fu-
ture numbers of ESRD patients and relevance as well
as cost-effectiveness of screening and intervention. Fi-
nally, this calls into question the wisdom of the K/DOQI
definition of “stages” of CKD rather than “grades” or
“classes”; a stage is by definition a transitory step toward
an end (ESRD in this case), while a grade or a class does
not have a connotation of progression.
Are screening tests for CKD reliable?
K/DOQI [23] and PARADE [13] have recommended
that screening be undertaken by urine dipstick analysis. A
positive test should be repeated within 3 months and sub-
sequently confirmed by a quantitative estimation of albu-
minuria/proteinuria such as a urine albumin/creatinine
ratio (ACR) [13]. Of note, different thresholds need to
be defined for abnormal ACR in males (>2.5 mg/mmol)
and females (>3.5 mg/mmol) [26]. A review of cost-
effectiveness of proteinuria dipstick tests concluded that
their sensitivity averages 76% with a specificity of around
79% [27]. Such accuracy would be acceptable if, as rec-
ommended, positive tests are repeated and subsequently
validated. Albuminuria also performs well as a screen-
ing test for proteinuria in the general population; the
AusDiab study showed that albuminuria was highly sen-
sitive (91.7%) and specific (95.3%) for detecting pro-
teinuria in the general Australian population [28]. From
the cost-effectiveness of screening for CKD viewpoint,
only routine and cheap dipsticks are a realistic option.
The more expensive and more sensitive and specific Al-
bustix might not be a cost-effective option unless we take
into consideration the cardiovascular implications of al-
buminuria detection. Therefore tools are available to us
for screening for proteinuria at a relatively affordable
cost and with an acceptable degree of accuracy.
In NHANES III, serum creatinine measurements var-
ied by as much as 25% [14]. Measurement of serum
creatinine will have to undergo rigorous calibration and
standardization to avoid inaccuracies and variability [14].
Also, estimation of renal function from serum creatinine
should take into consideration all the confounding factors
such as gender, age, race, muscle mass, timing, and diet.
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The calculation of GFR will have to rely on formulas val-
idated for given subgroups of individuals depending on
their stage of CKD and ethnicity [15].
Prognostic significance of albuminuria and proteinuria
Little doubt exists that patients with established
nephropathies have a worse prognosis in the presence
of heavy and sustained proteinuria [29, 30], and evidence
is emerging regarding the prognostic significance of pro-
teinuria and albuminuria in the general population [10,
21]. Studies undertaken in Okinawa after 17 years of
follow-up indicate that individuals with dipstick-positive
proteinuria are at increased risk, proportional to the
severity of proteinuria, of developing CKD [31]. Also,
data derived from the Prevention of Renal and Vascu-
lar End-Stage Disease (PREVEND) study in Groningen
revealed that albuminuria is associated with the subse-
quent development of CKD [32]. Furthermore, individ-
uals with albuminuria in the PREVEND study were at
increased risk of all-cause death as well as cardiovascular
mortality [10, 21]. Similar observations were made in the
EPIC-Norfolk study in the UK [33]. These findings sup-
port numerous reports linking albuminuria in the general
population, hypertensive as well as diabetic individuals,
with the subsequent development of cardiovascular dis-
ease (CVD) [33–36]. Albuminuria has been associated
with the cardiometabolic syndrome predisposing patients
to diabetes, hypertension, and CVD [37, 38]. Albumin-
uria might be a marker of vascular inflammation as well
as endothelial damage and dysfunction with a resulting
leakage of albumin from vascular and glomerular beds.
Proteinuria is also one of the most predictive markers of
CKD [22, 29–31].
The detection of CKD identifies patients at risk of car-
diovascular complications; increasing evidence suggests
that there is a steady increase in CVD morbidity and mor-
tality with declining renal function [18–20, 39]. In some
studies of hypertensive patients with and without left-
ventricular hypertrophy, proteinuria and raised serum
creatinine were higher risk markers for CVD than were
elevation of blood pressure or dyslipidemia [37].
Can interventions prevent or retard CKD?
An increasing number of patients treated by RRT
worldwide suffer from diabetic nephropathy and hyper-
tension. In the US and some European countries, diabetic
nephropathy is the leading cause of ESRD, accounting for
more than 40% of patients [40, 41]. This situation is likely
to worsen over the next 20 years as the number of patients
suffering from diabetes, mainly type 2, will increase from
154 million to 370 million; this increase will be most no-
ticeable in the developing countries, where the number of
diabetics will triple from 99 million to 286 million [42]. Di-
abetic nephropathy already accounts for more than 30%
to 40% of ESRD in countries such as Malaysia, Turkey,
Korea, Qatar, and the Philippines [42]. Changing trends
in the etiology of ESRD in some European countries also
show an increase in type 2 diabetic nephropathy and in
the number of patients with hypertension and renovas-
cular disease [43].
As with diabetes mellitus, the global burden of hy-
pertension is due to increase over the next decade [44].
Almost one-third of the population is projected to have
hypertension by 2025, an increase of around 60% with a
total of 1.56 billion affected [44].
The global rise in the number of overweight and obese
individuals is likely to have an impact on type 2 diabetes,
hypertension, and CKD. In fact, obesity is the sole risk
factor that is currently increasing in parallel with the rise
in ESRD [45].
Type 2 diabetes mellitus (DM), obesity, and hyperten-
sion are potentially preventable diseases. Research in
China [46], the US [47], some parts of Europe, Finland
[48], and Sweden [49] has shown that lifestyle modifi-
cations, including weight loss and exercise, can reduce
the incidence of overt type 2 DM in overweight patients
with impaired glucose tolerance by one-half. Similar re-
sults were reported with the insulin-sensitizing agent met-
formin [47]. In addition, recent evidence suggests that
angiotensin-converting enzyme (ACE) inhibition also
prevents the onset of albuminuria in type 2 DM [50].
Whether this observation is due to a genuine preven-
tion of albuminuria or merely its normalization by treat-
ment is difficult to ascertain, because the patients were
not evaluated after ACE inhibitor administration was dis-
continued. Furthermore, ACE inhibition also might have
a salutary effect on the incidence of diabetes.
Hypertension is also preventable by lifestyle modifica-
tions including weight loss and a reduction in dietary salt
intake [51]. The Dietary Approaches to Stop Hyperten-
sion (DASH) diet, which includes a high intake of fruit
and vegetables as well as a reduction in saturated fat in-
take, has proven effective in reducing both systolic and
diastolic blood pressure [52, 53]. The DASH-sodium trial
showed an additive beneficial effect of combining dietary
salt restriction [53].
Lifestyle modifications have the potential to reduce
type 2 DM, obesity, and hypertension, but they are dif-
ficult to sustain. Also, their adaptability to low-income
societies is doubtful as this would require a cultural, soci-
etal, as well as economic shift. In low-economy societies,
economic forces push individuals to adopt “obesegenic”
diets [54]. Healthy diets are expensive; high-sugar, high-
fat diets as well as canned foods, which are highly salted,
are much cheaper than fresh fruit and vegetables. Low-
income individuals might not even have the option of
exercise, as they have limited time for leisure and are
“time-poor” as well as cash-poor [54].
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Social deprivation has been shown in numerous sur-
veys including NHANES III to be a risk factor/marker
for CKD [9]. Pharmacologic approaches aimed at weight
loss might be more successful, although agents such as
sibutramine (a central norepinephrine and serotonin re-
uptake inhibitor) and orlistat (a gastric pancreatic lipase
inhibitor) are not without their side effects, thus reducing
compliance and sustainability [55]. Surgical bariatric in-
terventions have been advocated for morbid obesity with
good short-term results but decreasing efficacy at 10 years
[56].
A large body of evidence suggests that reduction of
blood pressure and proteinuria can lower the rate of
progression of CKD in patients with diabetic and non-
diabetic nephropathy by as much as 50% [30, 57]. In most
of these studies, ACE inhibition or the use of angiotensin-
receptor blockers (ARBs) has proven protective through
combined antihypertensive and antiproteinuric effects
[57]. The protective effect of these agents might be pro-
portional to their proteinuria-lowering effects [30]. Re-
duction of albuminuria and proteinuria is key to the
prevention of the progression of diabetic nephropathy.
Remuzzi’s group has argued that aggressive and multi-
factorial risk reduction interventions can either normal-
ize the annual rate of loss of renal function or even reverse
the trend [30]. In high-risk ethnic minorities such as the
Northern Territories’ Aborigines, treatment with an ACE
inhibitor not only decreased the incidence of ESRD but
also reduced mortality rates [58]. It is of interest that when
such treatment programs had to be discontinued because
of administrative difficulties, there was a surge in both
morbidity and mortality within a short period of time
[57].
Is screening for CKD cost-effective?
A model simulation based on the Markov model has
consistently shown that screening diabetic patients for al-
buminuria is cost-effective [27]. In the RENAAL study,
treatment with the ARB losartan reduced albuminuria
and slowed the progression of type 2 diabetic nephropa-
thy [59]. In this study, a reduction by 28.6% of the risk of
ESRD was estimated to lead to a net savings per patient in
ESRD-related cost at 3.5 years by $3522; net cost savings
per patient at 3.5 years (between $11,000 and $12,000)
was the highest in those with the highest baseline albu-
minuria (>4000 mg/g creatinine) [59]. In another study,
treatment with another ARB, irbesartan, in patients with
type 2 diabetic nephropathy led to an average cost sav-
ings of as much as $11,922 per patient after 25 years [60].
In non-diabetic nephropathies, similar simulation mod-
eling demonstrated that a reduction of 10%, 20%, and
30% of the rate of progression of CKD in patients with
GFR <30 mL/min led over 10 years to a cost saving of
$9 billion, $19 billion, and $33 billion, respectively [17].
Such cost savings were projected to be twice as high if
treatment was applied earlier to patients with GFRs of
<60 mL/min [17]. Little doubt exists, then, that slowing
the progression of established diabetic and non-diabetic
nephropathies leading to delay or prevention of ESRD
is cost-effective.
It is not as clear, however, whether general popula-
tion screening for proteinuria by dipstick testing is cost-
effective. One study concluded that, in patients under the
age of 60 years, the cost of screening for proteinuria would
be $282,818 per quality-adjusted life-year compared to
$53,3272/QALY in those over 60 years [27]. Thus the
cost of screening and treating patients with CKD under
the age of 60 was not deemed cost-effective. However,
this analysis did not take into consideration the cost- and
life-saving potential of proteinuria detection on CVD.
Screening individuals identified at risk of CKD, such as
diabetic and hypertensive individuals, the elderly, as well
as relatives of patients with CKD, is likely to be more
cost-effective as long as these individuals would represent
a substantial proportion of future patients with ESRD.
Screening patients with diabetes, hypertension, at-risk
ethnic minorities, or relatives of patients with CKD is
likely to be the way forward. The US National Kidney
Foundation Kidney Early Evaluation Program (KEEP)
has detected functional or structural abnormalities in
47% of high-risk individuals screened [61]. Such a high
prevalence of CKD would justify screening and prove
cost-effective.
Recommendations
Screening high-risk individuals should be the priority.
Those would include diabetics, hypertensives, at-risk eth-
nic minorities, the elderly, and relatives of patients with
CKD [13, 61]. Other at-risk individuals include patients
with autoimmune diseases known to affect the kidney.
Whole-population screening might be too costly and not
as cost-effective [27]. Screening should consist of dipstick
testing for proteinuria with confirmatory re-testing within
3 months. Persistent abnormalities would then be vali-
dated by an estimation of spot urine ACR [13, 23]. A
raised ACR would justify further functional, radiologic,
and/or histologic investigations.
Having established the need for screening at-risk in-
dividuals for proteinuria, it remains to be determined
how such screening would be implemented. In Western
countries, this is most likely to take place in the primary
care setting. In developing countries, screening individu-
als within rural areas where the majority of patients with
CKD reside would require considerable staffing. Most de-
veloping countries are in shortage of doctors and nurses
[62, 63]. There is a massive “brain drain” of skilled medi-
cal workers away from Africa and the Far East. It has been
estimated that in Africa around 20,000 skilled workers,
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Table 1. Nephrologists and their training in some sub-Saharan African countries
Somalia Ethiopia Tanzania Kenya Sudan Congo Republic Chad Nigeria
Population, millions 8.4 67 36.3 30 30 3.5 9.2 130
Nephrologists 0 7 0 16 15 3 0 50
Nephrology training, months 0 2 0 4 4 3 0 24
Table modified from [64].
including doctors, leave the continent every year. They
are lured by a better standard of living in the West and
disillusioned by the lack of opportunities at home [63].
In Africa, the majority of sub-Saharan countries have a
handful of nephrologists located primarily in urban cen-
ters [64] (Table 1). It is unlikely that one nephrologist
for 10 million people would be able to implement detec-
tion and prevention of CKD programs. It is more likely
that such an initiative will depend heavily on health care
workers who live in rural areas and can be trained within
days to perform the necessary screening tests [65]. Such
screening initiatives have been successful in Australian
Aborigines [66], in the Chennai community of southern
India [65], and in Soweto in South Africa [67]. The suc-
cess of these programs depended heavily on the dedica-
tion and commitment of health care workers to screen,
educate, and treat CKD patients. They would report to a
local doctor and act under the guidance of the nephrology
program leader.
Having established the need for screening for CKD to
initiate primary and secondary preventive measures, the
question remains that of funding and infrastructural sup-
port for such programs. Logically, government agencies
should take the lead. However, reluctance due to lim-
ited funds and conflicting health care priorities militates
against their involvement. They might require concrete
evidence of cost-effectiveness before committing scarce
resources and shifting health care priorities [68]. Conse-
quently, it might be necessary to recruit the support of
non-governmental organizations (NGOs), charities, and
the pharmaceutical industry to offer financial assistance.
The pharmaceutical industry might see an advantage in
supporting screening initiatives, as they would provide an
untapped pool of potential customers [69]. Data collected
through pilot studies subsequently might encourage re-
luctant governments to become involved.
In summary, the patient we discussed today highlights
the desperate plight of millions of patients with CKD who
are denied renal replacement therapy because of a lack
of dialysis facilities in the majority of developing coun-
tries. These patients are left with the sole option of death
or asylum in a country that can provide them with the
lifesaving treatment that they so desperately need. The
future would seem darker and gloomier if it weren’t for
an upsurge of global initiatives aimed at the detection
of CKD and its prevention. These should be targeted to
populations at risk to maximize their cost-effectiveness.
The programs should involve nephrologists but also pri-
mary care physicians and should rely heavily on dedicated
health care workers. These initiatives should call upon
the support of governments but also of NGOs and the
pharmaceutical industry. A global task force is needed to
coordinate these programs; the International Society of
Nephrology Commission for the Global Advancement of
Nephrology (ISM COMGAN) has taken a lead through
its research committee by setting regional networks to
foster detection and prevention of CKD initiatives.
QUESTIONS AND ANSWERS
PROF. RASHAD BARSOUM (Cairo University, Cairo,
Egypt): The pragmatic issue is whether we should screen
for diabetes and hypertension or whether we should
screen diabetics and hypertensives for microalbuminuria
and evidence of CKD. We know that if someone is di-
abetic, it might be worthwhile to treat him with ACE
inhibitors or ARBs as well as statins without having to
screen for microalbuminuria. The same might apply to
hypertensive patients. Would you care to expand on that?
PROF. EL NAHAS: There is no question that we need to
identify diabetics and hypertensives in the general popu-
lation, as untreated diabetes and poorly controlled hyper-
tension bear considerable cardiovascular risks. We also
know that a 5 mm Hg reduction in average diastolic blood
pressure reduces the risk of stroke by as much as 40%.
The DCCT study showed that for every 10% reduction in
glycosylated hemoglobin, we can expect a 40% reduction
in cardiovascular complications. Mani and co-workers in
India showed that both hypertension and diabetes are un-
derdiagnosed in a large percentage of rural communities,
that detection programs are feasible at low cost if health
care workers are used, and that effective treatment can
be achieved on a limited budget [65].
Regarding screening diabetics and hypertensives for
microalbuminuria and CKD, most guidelines recommend
such screening, although debates are ongoing about the
value of screening patients with type 2 diabetes. Iden-
tifying those at increased risk offers the advantage of a
concentrated effort at reducing their cardiovascular and
renal risks. Unfortunately, most surveys have shown that
the percentage of those screened remains unacceptably
low.
DR. GARABED EKNOYAN (Baylor College of Medicine,
Houston, Texas): I would like to make a few points. The
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first relates to the NHANES III data that you men-
tioned. In fact, serum creatinine measurement was stan-
dardized before GFR calculations were made using the
MDRD formula. Also, although proteinuria was not re-
peatedly measured in all the participants of the survey,
the data were calculated based on those with persistent
proteinuria as highlighted in the survey report; I guess
these details have not filtered through and this has led to
misconception of the data.
The second point I would like to make relates to the
word “screening.” I think we should avoid the word
screening and talk of detection. Most screening programs
in medicine did not live up to their initial promise. Re-
garding CKD detection, we should be careful and set
progressive goals, starting by looking at our own prac-
tices before we go global. Data from many centers have
consistently shown that we fail in a significant number
of patients to achieve targets and objectives such as BP
control, use of ACE inhibitors/ARBs, and calcium and
phosphate control, in CKD. We therefore need to care-
fully develop models for detecting CKD and models for
implementing treatment based on realistic feasibility and
expectations, not on idealized models.
PROF. EL NAHAS: Regarding the NHANES III-
derived data suggesting that over 10% of the US adult
population has some element of CKD, it is imperative
that such data be verified prospectively and those at risk
defined so we can avoid being alarmist and unrealistic.
Studies underway in the US and supported by the NIH
[Chronic Renal Insufficiency Cohort (CRIC)] and some
planned in the UK, including Sheffield, will allow us to
have more definitive data either confirming or refuting
such an alarming prospect. The question of achieving tar-
gets for detection (such as microalbuminuria in diabet-
ics) or treatment in CKD is a real issue that might reflect
the fact that guidelines and targets are slow to filter down
through the various tiers of the medical profession. In the
UK, the government is encouraging primary care physi-
cians to meet treatment targets through quality initiatives
with financial incentives; this might be one way forward.
DR. EKNOYAN: My question takes us back to the case
of the unfortunate young sub-Saharan woman you pre-
sented. Are you advertising the fact that if patients in
countries where RRT is not available travel to the West,
dialysis will be offered with no restrictions? I face a similar
dilemma in Houston with patients traveling from neigh-
boring Mexico.
PROF. EL NAHAS: This is the question I was hoping
would not be asked. It is a politically loaded issue in our
day and age when debates rage in Europe on immigra-
tion and asylum seeking. There is a trend to encourage the
immigration of those who are fit and capable of serving
Western societies by providing much needed manpower
and to discourage as well as limit that of others. The case
of the patient I reported here illustrates the fact that be-
side politically or economically motivated immigration,
there are those who come to the West seeking “medi-
cal asylum.” These patients are at as much, if not higher,
risk of death compared to political refugees. When con-
fronted with such patients, we as doctors should do our
utmost to provide them with treatment options regardless
of political or administrative considerations.
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine, Boston, Massachusetts): There
are recent arguments in the US that one of the determi-
nants of a person’s health status is not the ability to get to
a physician, but rather social class and economic status.
Many of the socially deprived suffer poor health because
of a lack of awareness and education. Should we there-
fore divert some of our health care resources to general
education? There is little doubt that educating individu-
als in developing countries, particularly women, thereby
increasing family assets, would lead to greater health for
that family and its descendents.
PROF. EL NAHAS: There is little doubt that social and
economic deprivation is a risk factor for the development
of CKD as shown by NHANES III. We have just com-
pleted a small survey in Sheffield that showed that a sig-
nificantly higher number of patients presented with CKD
from low socio-economic classes. In my talk, I stressed
the importance of education and awareness. Evidence
suggests that people in general have little awareness of
renal disease. Also, primary care physicians are not al-
ways fully aware of the scope and implications of CKD;
their education is of paramount importance if we hope
to implement more effective detection and management
of CKD programs. Efforts are already underway with
that emphasis, including the Disease Education Program
launched by the US National Kidney Foundation (NKF)
in 2004. Overall, diverting some resources from health
care to education might be a cost-effective way of im-
proving primary prevention of chronic diseases including
CKD.
DR. AHMED ADAM (University of Alexandria, Alexan-
dria, Egypt): Do you think that more needs to be done
by governments within the developing countries to im-
prove public education in relation to lifestyle changes to
prevent CKD?
PROF. EL NAHAS: This is an important and topical is-
sue not only in the West but also in developing countries,
where western lifestyles are adopted. The world popu-
lation over the last 50 years has adopted increasingly
sedentary lifestyles with limited exercise and overeating.
Obesity is becoming a global threat and pandemic with
links to hypertension, diabetes, and CKD. Interestingly,
Western societies and their socio-economic infrastructure
often mitigate against a healthy lifestyle; recently, a very
informative editorial in the Lancet by McCarthy high-
lighted the social forces and difficulties facing obese in-
dividuals who would like to change their lifestyle [54].
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In the UK, the government recently started a campaign
to improve lifestyle and discourage high salt and calorie
intake, promote exercise, and encourage smoking ces-
sation. Such initiatives can start early in life with ed-
ucational programs at school, and it could be decades
before we reap the benefits of such initiatives in terms
of disease risk reduction. In the US, the National Kidney
Foundation launched its Disease Education Program in
2004.
DR. MOHAMED HAFEZ (Cairo University): In the
PREVEND study, the response rate was almost 50%,
while in the KDIGO survey [70], the response from the
Middle East was a mere 5%. Do you think this poor
response reflects physicians’ frustration with the lack of
the public’s interest in being screened or changing their
lifestyle? Maybe an incentive for screening would be to
offer access to inexpensive, if not free, medical care.
PROF. EL NAHAS: You are right; for people to partic-
ipate in detection programs, they have to be motivated
by the knowledge of the impact disease can have on their
health and the assurance that detection will mean preven-
tion and/or treatment. This takes us back once more to
the issue of population education and awareness of CKD
and related complications. The PREVEND example of
high response and population participation also might
reflect the social behavior of the people of Groningen. I
doubt that a similar response rate would have been ob-
tained, for instance, in Amsterdam; I recall in the 1980s
how compliant the CKD patients of Groningen were to
a low-protein diet, unlike their Amsterdam counterparts.
Regarding provision of treatment for those with hyper-
tension, diabetes, albuminuria, or CKD, we need not be
discouraged in the developing countries by the inaccessi-
ble cost of medications such as ACE inhibitors and ARBs;
good and comparable results have been achieved with
cheaper and older drugs such as thiazide diuretics, hy-
dralazine, and reserpine [65]. We also need to remind the
pharmaceutical industry of its duty toward provision of
accessible care in developing countries.
DR. METWALLY EL SHAHAWY (Benha University,
Benha, Egypt): Would you please expand on your refer-
ence to the DASH study, which suggested that combining
the DASH diet with a low salt intake was additive in its
antihypertensive effect?
PROF. EL NAHAS: In general, the DASH diet leads to
lower systolic and diastolic blood pressures when com-
pared to ordinary diets. Also, the DASH-sodium studies
showed that a low dietary salt intake (∼60 mmol/day)
combined with a DASH diet further reduces blood pres-
sure. In general, we don’t pay enough attention to dietary
salt restriction in the management of patients with CKD;
I would like to refer you to an excellent review article
published in the American Journal of Kidney Disease that
discusses the role of dietary salt restriction in CKD [71].
The difficulty with sustained salt restriction is compliance;
for that, we advise our patients to reduce consumption of
processed food, which is rich in salt, and to avoid adding
salt to food at the table.
DR. EL SHAHAWY: Would screening for albuminuria
be of value in detecting industrial and environmental
nephrotoxicity?
PROF. EL NAHAS: Numerous studies have examined
toxic industrial exposure and renal function; some of the
UK studies in the 1990s were performed in Liverpool
in automobile workers [72]; in 1995, Stevenson et al de-
tected tubular injury and dysfunction based on the pres-
ence of high levels of proximal tubule enzymuria [72]. It
is unlikely that measurement of microalbuminuria would
be of value in such patients although decreased reabsorp-
tion of filtered albumin due to proximal tubule damage
could be manifested by increased urinary excretion. They
also noted circulating markers of glomerular basement
membrane damage induced by hydrocarbon exposure,
including auto-antibodies to basement membrane com-
ponents. As far as environmental nephrotoxicity in Egypt
is concerned, this has been a subject of concern over many
years. Exposure to lead, mercury, and cadmium all have
been mentioned. In the US, chronic lead exposure has
been linked to increased serum creatinine levels [73]. But
little hard evidence implicates environmental pollution as
a major factor in the rising incidence of CKD and ESRD
in Egypt.
DR. MOHAMED ZAATER (Cairo University): Would
you please comment on the role of uric acid on progres-
sion of CKD? Do you think clinical trials on the use of
allopurinol on CKD progression are warranted?
PROF. EL NAHAS: This is an interesting and timely
question, as there is mounting experimental data link-
ing uric acid to hypertension and possibly CKD. Dr. Rick
Johnson in Florida and Dr. Agnes Fogo in Nashville have
put forward a hypothesis stipulating the nephrotoxicity of
hyperuricemia [74]. Work by Johnson’s group confirmed
an association in experimental models between uric acid
and hypertension as well as kidney scarring [75]. A grow-
ing body of evidence links hyperuricemia to increased car-
diovascular risk [76]. However, more evidence is needed
before we prescribe allopurinol to asymptomatic CKD
patients with hyperuricemia. Regarding clinical trials in
CKD, it is imperative that they be adequately powered;
too many clinical trials undertaken in nephrology have
been underpowered in the past and therefore inconclu-
sive. Trials in CKD require a large number of patients
followed for long periods. In the UK and the EU, trials
have to comply with Good Clinical Practice (GCP) reg-
ulations on the conduct of clinical investigation.
DR. SALAH NAGA (Alexandria University): I would
like to raise the important issue of drug-induced nephro-
toxicity in developing countries, where many drugs in-
cluding nonsteroidal anti-inflammatory drugs (NSAIDs)
are available over the counter.
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PROF. EL NAHAS: That is a very important issue. There
is little doubt that in many countries where NSAIDs
are readily available over the counter they can affect
long-term kidney function. Of interest, the odds ratio
for ESRD is high with NSAIDs (up to 8.8 in one large
study of 716 patients) but interestingly not with as-
pirin [77]. This difference might be due to the stimula-
tion by aspirin of the release of lipoxygenase interaction
products (lipoxins; aspiring-triggered lipoxins) that have
anti-inflammatory and anti-fibrotic effects. Another im-
portant issue in sub-Saharan Africa, where the patient we
discussed came from, is herbal remedies and their poten-
tial nephrotoxicity and impact on CKD and its progres-
sion (reviewed in [78]). It is important that we be aware
of the potential nephrotoxicity of such remedies in the
developing world.
DR. GAMAL SAADI (Cairo University): You showed
some cost-effectiveness of screening older individuals
rather than the young population. However, it would
make good sense to screen and educate the youngest;
it would, for instance, be advisable to start screening at
school level to detect albuminuria, glucosuria, and uri-
nary tract infections. Would you recommend such an ap-
proach, and what would the age cut-off be?
PROF. EL NAHAS: This takes us back to the timing and
target of general population screening. The study I re-
ferred to by Boulware et al [27] was based on computer
modeling, and simulation showed that it was more cost-
effective for screening those over 50 years of age. Re-
garding screening children, this has been undertaken by
the National Kidney Foundation of Singapore (NKFS),
where they found up to 6% hematuria in school children
[12]. However, before we embark on an across-the-board
screening project, we need to ascertain the implications
and cost. I suspect that in view of the low prevalence of
ESRD in children, screening might not be cost-effective.
The NKFS model with community-based “prevention
centers” might be an experiment worthwhile following
[79].
DR. AHMED ADEL HASSAN (Zagazig University,
Zagazig, Egypt): As you are aware, hepatitis C is endemic
in Egypt. Should we therefore screen patients who are
carriers for hepatitis C for microalbuminuria?
PROF. EL NAHAS: I would have thought that in view
of the high prevalence of hepatitis C infection in Egypt
(up to 25% in some age groups) and the association be-
tween hepatitis C infection and CKD, it would be worth-
while identifying those who have microalbuminuria, as it
could highlight a subgroup at increased risk of CKD and
CVD. In fact, recently published data derived from the
US NHANES III showed a higher prevalence (around
12%) of microalbuminuria among patients positive for
hepatitis C [80]. This should prompt further investiga-
tion of this important epidemiologic area so pertinent to
Egypt.
PROF. AHMED ELBELBESSI (Alexandria University): I
would like to know how you obtained data on provision
of renal care in sub-Saharan countries.
PROF. EL NAHAS: You touch upon an important issue
here. Renal data collection from Africa and most of the
developing world is poor. Most countries don’t have a re-
nal registry, and the ones that do are vulnerable to incom-
plete data collection. Most of the data I presented came
from Prof. Sarala Naicker, Chair of COMGAN’s Africa
committee. She undertook a postal survey to ascertain
the levels of nephrologic services in African countries.
There is a sharp contrast between nephrology health care
in northern African countries like Egypt, Tunisia, and
Morocco, as well as South Africa, where nephrologists
and dialysis provision are satisfactory, and sub-Saharan
African countries, where huge deficiencies exist in service
provision.
DR. EL EISH (Alexandria, Egypt): While hyperten-
sion and diabetes are common causes of CKD in adults,
they constitute a small percentage of children with CKD.
Should we treat children with CKD who are normoten-
sive and have no proteinuria with ACE inhibitors or
ARBs?
PROF. EL NAHAS: Dysplastic kidneys and reflux
nephropathy are common causes of CKD in children.
Whether we should treat those who are normotensive and
with no proteinuria is an interesting question. I think that
they should be screened for microalbuminuria. Also, all
too often we assume that patients with CKD have normal
blood pressure when in reality their blood pressure levels
are high for their age and gender. Further, we don’t mea-
sure 24-hour ambulatory blood pressure often enough in
“normotensive” CKD patients who might have lost the
nocturnal blood pressure dip. I think that those defined as
pre-hypertensive (JNC VII) and those with progressive
microalbuminuria should be treated. ACE inhibition is
protective in reflux nephropathy [81]. On the other hand,
if renal function is stable, and in the absence of albu-
minuria, I would recommend observing and monitoring
CKD rather than prescribing ACE inhibitors or ARBs
when they are not indicated.
DR. HARRINGTON: You said little about sources of
funding for detection and prevention programs. To ap-
proach governments as well as NGOs, we need to have
careful and specific plans. How should we collectively
put together grant proposals that have chances of being
funded to address the huge demands and issues addressed
in your lecture?
PROF. EL NAHAS: Many national organizations and
kidney foundations including those in the US are
putting together carefully thought through strategic
plans. Many initiatives are underway, as recently re-
viewed by Eknoyan and colleagues [82]. I referred pre-
viously to the efforts of the NKF of Singapore. In the
UK, discussions are underway for a national detection
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and prevention of CKD strategy. Globally, the ISN and
COMGAN under the leadership of John Dirks (Chair)
and Giuseppe Remuzzi (Chair for Research) have made
huge efforts through setting up regional meetings to in-
crease awareness of CKD. A meeting was organized,
with the support of the Rockefeller Foundation, and at-
tended by representatives from the World Health Orga-
nization, in the spring of 2004 in Bellagio, Italy, involving
a number of interested nephrologists from developing
and developed countries to put together a global strategic
approach [83]. Since then, numerous regional initiatives
have been fostered by ISN COMGAN to facilitate de-
tection and prevention of CKD in developing countries.
We also need to engage the pharmaceutical industry to
provide much-needed research funds as well as supply
developing countries with necessary renoprotective and
cardioprotective drugs. Once data from pilot studies are
available, it will become much easier to convince govern-
ments to act.
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